398 related articles for article (PubMed ID: 30530630)
1. Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.
Lao JP; DiPrimio N; Prangley M; Sam FS; Mast JD; Perlstein EO
G3 (Bethesda); 2019 Feb; 9(2):413-423. PubMed ID: 30530630
[TBL] [Abstract][Full Text] [Related]
2. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
3. A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency.
Westphal V; Kjaergaard S; Schollen E; Martens K; Grunewald S; Schwartz M; Matthijs G; Freeze HH
Hum Mol Genet; 2002 Mar; 11(5):599-604. PubMed ID: 11875054
[TBL] [Abstract][Full Text] [Related]
4. Evolutionary rescue of phosphomannomutase deficiency in yeast models of human disease.
Vignogna RC; Allocca M; Monticelli M; Norris JW; Steet R; Perlstein EO; Andreotti G; Lang GI
Elife; 2022 Oct; 11():. PubMed ID: 36214454
[TBL] [Abstract][Full Text] [Related]
5. The Analysis of Variants in the General Population Reveals That
Citro V; Cimmaruta C; Monticelli M; Riccio G; Hay Mele B; Cubellis MV; Andreotti G
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061496
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations.
Vega AI; Pérez-Cerdá C; Abia D; Gámez A; Briones P; Artuch R; Desviat LR; Ugarte M; Pérez B
J Inherit Metab Dis; 2011 Aug; 34(4):929-39. PubMed ID: 21541725
[TBL] [Abstract][Full Text] [Related]
7. Genotypes and estimated prevalence of phosphomannomutase 2 deficiency in Turkey differ significantly from those in Europe.
Yıldız Y; Arslan M; Çelik G; Kasapkara ÇS; Ceylaner S; Dursun A; Sivri HS; Coşkun T; Tokatlı A
Am J Med Genet A; 2020 Apr; 182(4):705-712. PubMed ID: 31981409
[TBL] [Abstract][Full Text] [Related]
8. The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein.
Yuste-Checa P; Gámez A; Brasil S; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
Hum Mutat; 2015 Sep; 36(9):851-60. PubMed ID: 26014514
[TBL] [Abstract][Full Text] [Related]
9. A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.
Chan B; Clasquin M; Smolen GA; Histen G; Powe J; Chen Y; Lin Z; Lu C; Liu Y; Cang Y; Yan Z; Xia Y; Thompson R; Singleton C; Dorsch M; Silverman L; Su SM; Freeze HH; Jin S
Hum Mol Genet; 2016 Jun; 25(11):2182-2193. PubMed ID: 27053713
[TBL] [Abstract][Full Text] [Related]
10. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.
Schiff M; Roda C; Monin ML; Arion A; Barth M; Bednarek N; Bidet M; Bloch C; Boddaert N; Borgel D; Brassier A; Brice A; Bruneel A; Buissonnière R; Chabrol B; Chevalier MC; Cormier-Daire V; De Barace C; De Maistre E; De Saint-Martin A; Dorison N; Drouin-Garraud V; Dupré T; Echenne B; Edery P; Feillet F; Fontan I; Francannet C; Labarthe F; Gitiaux C; Héron D; Hully M; Lamoureux S; Martin-Coignard D; Mignot C; Morin G; Pascreau T; Pincemaille O; Polak M; Roubertie A; Thauvin-Robinet C; Toutain A; Viot G; Vuillaumier-Barrot S; Seta N; De Lonlay P
J Med Genet; 2017 Dec; 54(12):843-851. PubMed ID: 28954837
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG.
Yuste-Checa P; Brasil S; Gámez A; Underhaug J; Desviat LR; Ugarte M; Pérez-Cerdá C; Martinez A; Pérez B
Hum Mutat; 2017 Feb; 38(2):160-168. PubMed ID: 27774737
[TBL] [Abstract][Full Text] [Related]
12. Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies.
Chong M; Yoon G; Susan-Resiga D; Chamberland A; Cheillan D; Paré G; Seidah NG
J Med Genet; 2020 Jan; 57(1):11-17. PubMed ID: 31391289
[TBL] [Abstract][Full Text] [Related]
13. Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).
Thiesler CT; Cajic S; Hoffmann D; Thiel C; van Diepen L; Hennig R; Sgodda M; Weiβmann R; Reichl U; Steinemann D; Diekmann U; Huber NM; Oberbeck A; Cantz T; Kuss AW; Körner C; Schambach A; Rapp E; Buettner FF
Mol Cell Proteomics; 2016 Apr; 15(4):1435-52. PubMed ID: 26785728
[TBL] [Abstract][Full Text] [Related]
14. Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia.
Westphal V; Peterson S; Patterson M; Tournay A; Blumenthal A; Treacy EP; Freeze HH
Genet Med; 2001; 3(6):393-8. PubMed ID: 11715002
[TBL] [Abstract][Full Text] [Related]
15. A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency.
Cline A; Gao N; Flanagan-Steet H; Sharma V; Rosa S; Sonon R; Azadi P; Sadler KC; Freeze HH; Lehrman MA; Steet R
Mol Biol Cell; 2012 Nov; 23(21):4175-87. PubMed ID: 22956764
[TBL] [Abstract][Full Text] [Related]
16. Primary ovarian insufficiency in a female with phosphomannomutase-2 gene (PMM2) mutations for congenital disorder of glycosylation.
Masunaga Y; Mochizuki M; Kadoya M; Wada Y; Okamoto N; Fukami M; Kato F; Saitsu H; Ogata T
Endocr J; 2021 May; 68(5):605-611. PubMed ID: 33583911
[TBL] [Abstract][Full Text] [Related]
17. PMM2-CDG: phenotype and genotype in four affected family members.
Bortot B; Cosentini D; Faletra F; Biffi S; De Martino E; Carrozzi M; Severini GM
Gene; 2013 Dec; 531(2):506-9. PubMed ID: 23988505
[TBL] [Abstract][Full Text] [Related]
18. A new insight into PMM2 mutations in the French population.
Le Bizec C; Vuillaumier-Barrot S; Barnier A; Dupré T; Durand G; Seta N
Hum Mutat; 2005 May; 25(5):504-5. PubMed ID: 15844218
[TBL] [Abstract][Full Text] [Related]
19. Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2.
Andreotti G; Monti MC; Citro V; Cubellis MV
PLoS One; 2015; 10(10):e0139882. PubMed ID: 26488408
[TBL] [Abstract][Full Text] [Related]
20. Renal involvement in PMM2-CDG, a mini-review.
Altassan R; Witters P; Saifudeen Z; Quelhas D; Jaeken J; Levtchenko E; Cassiman D; Morava E
Mol Genet Metab; 2018 Mar; 123(3):292-296. PubMed ID: 29229467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
